Indication 
Type 
Form 
Target 
Clinical progress 
Estimated launch time Product Introduction
Our Semaglutide Tablets represents a significant advancement in medication, leveraging our cutting-edge oral delivery technology. This technology facilitates effective oral absorption of biopharmaceuticals through a targeted delivery system. Additionally, our tablet utilizes a unique excipient technology that ensures both stabilization and enhanced penetration. This combination of targeted delivery and advanced excipient technology underscores our commitment to pioneering innovations in drug delivery, providing patients with a more effective and convenient therapeutic option..
Research Data
[Biovailability in Beagle Dog: Single-dose h2h PK study]
The AUC of BO-017 mg capsule is 12 times higher than the Rybelsus 7 mg tablet.
[Primate research data: Comparison of promate absorption after a single dose]
|
Item |
Specification |
Subject |
Number |
AVG Cmax (ng/ml) |
AVG T1/2 (hours) |
Bioavailability |
|
Rybelsus |
5 mg |
normal |
n=24 |
8.3 |
7.94 |
0.4~1%(3) |
|
Rybelsus |
7 mg |
normal |
n=6 |
4.37 |
/ |
0.4~1%(3) |
|
BO-01 |
7 mg |
normal |
n=5 |
62.6 |
51.6 |
/ |
(1)Originated from Rybelsus EMA NDA data
(2)In-house data
(3)Originated from Rybelsus FDA NDA data
BO-01 displayed~8 times higher than Rybelsus when concerning their single-dose Cmax.
BO-01 displayed~7 times higher than Rybelsus when concerning their single-dose T1/2.
Our Advantages
From a Polypeptide molecule to an IND Product
Oral Semaglutide Delivery Technology:
● Fully independent intellectual property
● High bioavailability
● Low material cost
● Safe excipients
● Extended drug half-life
From a IND Product to a Launch Product
R&D Platform Advantage:
● Controlled aplification
● Validated delivery
● QC compliance
Project Cooperation
Product License-out
● Biosimilar polypeptide molecules
● 2.2/505b (2) development
● Liscense-out at early/late clinical stage
Technique License-out
When considering technique license-outs, we offer a comprehensive approach that caters to client-specific needs and supports the development of Type 1 original drugs and client-owned polypeptides. Our licensing model includes structured agreements with milestone fees, ensuring collaborative advancement from initial stages through to regulatory milestones. This approach not only fosters innovation but also facilitates strategic partnerships aimed at accelerating the delivery of novel therapeutics to market.
Certificate Display
Exhibition Photos
Company Profile
FAQ
Q: 1.Is oral Semaglutide as effective as injectable semaglutide?
Although data is limited, Rybelsus® and Ozempic® seem to be providing similar results with weight reduction and blood glucose levels. Ozempic® equated to an average of 9.9 pounds lost over 30 days while Rybelsus® averaged 8.2 pounds lost over 30 days according to one study.
Q: 2.Whos should not take semaglutide?
Another is that these drugs are intended for diabetics, people with risks of heart issues, and overweight people who have struggled to lose or maintain their weight. They are not meant to be used to lose a quick five or ten pounds.
Q: 3.What side effects should people be aware of?
Stomach issues like nausea, bloat, or extreme fullness
Dizziness, headache, or fatigue
Gastrointestinal issues, such as diarrhea, constipation and gassiness
GI issues are the most common complaint among people just starting semaglutide. "This is a big reason working with a healthcare provider is important. We have the flexibility help patients maintain a dosage of the drug that they can tolerate and gradually increase over time," says Dr. Peterson.
Hot Tags: semaglutide tablets, China semaglutide tablets manufacturers, suppliers, Semaglutide Oral Tablets 7mg, 910463 68 2 Tablet, Semaglutide Tablets, 910463 68 2 Oral, Semaglutide Weight Loss Tablets, 910463 68 2 Weight Loss
